Skip to main content

Advertisement

SpringerLink
Log in

Current treatment and management of retinoblastoma

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Retinoblastoma was traditionally treated with enucleation and external-beam radiotherapy. However, in the past decade, systemic chemotherapy has become the primary globe-salvaging approach. This approach is generally combined with focal treatment, allowing for tumor consolidation following initial chemoreduction. A recently developed classification scheme may improve our ability to predict outcomes with this treatment modality. The Children’s Oncology Group has initiated a series of prospective multicenter trials to improve treatment outcomes with systemic chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Ferris FL III, Chew EY: A new era for the treatment of retinoblastoma. Arch Ophthalmol 1996, 114:1412.

    PubMed  Google Scholar 

  2. Murphree AL, Villablanca JG, Deegan WF III, et al.: Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996, 114:1348–1356.

    PubMed  CAS  Google Scholar 

  3. Kingston JE, Hungerford JL, Madreperlqa SA, Plowman PN: Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol 1996, 114:1339–1343.

    PubMed  CAS  Google Scholar 

  4. Shields CL, DePotter P, Himelstein BP, et al.: Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol 1996, 114:1330–1338.

    PubMed  CAS  Google Scholar 

  5. Lumbroso L, Doz F, Urbieta M, et al.: Chemothermotherapy in the management of retinoblastoma. Ophthalmology 2002, 109:1130–1136.

    Article  PubMed  Google Scholar 

  6. Abramson DH, Ellsworth RM, Kitchin FD, Tung G: Second nonocular tumors in retinoblastoma survivors. Are they radiation-induced? Ophthalmology 1984, 91:1351–1355.

    PubMed  CAS  Google Scholar 

  7. Abramson DH, Frank CM: Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology 1998, 105:579–580.

    Article  Google Scholar 

  8. Wong FL, Boice JD, Abramson DH, et al.: Cancer incidence after retinoblastoma radiation dose and sarcoma risk. JAMA 1997, 278:1262–1267.

    Article  PubMed  CAS  Google Scholar 

  9. Moll AC, Imhof SM, Schouten-Van Meeteren AY, et al.: Second primary tumors in hereditary retinoblastoma: a register-based study, 1945–1997: is there an age effect on radiation-related risk? Ophthalmology 1001, 108:1109–1114.

    Article  Google Scholar 

  10. Eng C, Li FP, Abramson DH et al.: Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993, 85:1121–1128.

    Article  PubMed  CAS  Google Scholar 

  11. Marcus DM, Brooks SE, Leff G, et al.: Trilateral retinoblastoma: insights into histogenesis and management. Surv Ophthalmol 1998, 43:59–70.

    Article  PubMed  CAS  Google Scholar 

  12. Shields, CL, Meadows AT, Shields JA, et al.: Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Arch Ophthalmol 2001, 119:1269–1272.

    PubMed  CAS  Google Scholar 

  13. Gallie B, Truong T, Heon E, et al.: Retinoblastoma ABC classification world survey. Presented at the 11th International Retinoblasoma Symposium. Paris, France; May 2003:66.

  14. Murphree AL: Intraocular retinoblastoma: the case for a new group classification. In Ophthalmology Clinics of North America, vol 18. Philadelphia: Elsevier Saunders; 2005:41–53.

    Google Scholar 

  15. McLean IW, Burnier M, Zimmerman L, Jakobiec F: Tumors of the retina. In Atlas of Tumor Pathology. Tumors of the Eye and Ocular Adnexa. Edited by McLean IW, Burnier MN, Zimmerman LE. Washington, DC: Armed Forced Institute of Pathology; 1994:100–135.

    Google Scholar 

  16. Sang DN, Albert DM: Retinoblastoma: clinical and histopathologic features. Hum Pathol 1982, 13:133–147.

    Article  PubMed  CAS  Google Scholar 

  17. Andersen SR, Jensen OA: Retinoblastoma with necrosis of central retinal artery and vein and partial spontaneous regression. Acta Ophthalmol 1974, 52:183–193.

    CAS  Google Scholar 

  18. Shields CL, Shields JA, Baez K, et al.: Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors. Cancer 1994, 73:69269–69268.

    Article  Google Scholar 

  19. Chong EM, Coffee RE, Chintagumpala M, et al.: Extensively necrotic retinoblastoma is associated with high-risk prognostic factors. Arch Pathol Lab Med 2006, 130:1669–1672.

    PubMed  Google Scholar 

  20. Spencer WH: Optic nerve extension of intraocular neoplasms. Am J Ophthalmol 1975, 80:465–471.

    PubMed  CAS  Google Scholar 

  21. Honavar SG, Singh AD, Shields CL, et al.: Does post-enucleation prophylactic chemotherapy in high risk retinoblastoma prevent metastasis? Invest Ophthalmol Vis Sci 2000, 41:S953.

    Google Scholar 

  22. Uusitalo MS, Van Quill KR, Scott IU, et al.: Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol 2001, 119:41–48.

    PubMed  CAS  Google Scholar 

  23. Deegan WF: Emerging strategies for the treatment of retinoblastoma. Curr Opin Ophthalmol 2003, 14:291–295.

    Article  PubMed  Google Scholar 

  24. Shields CL, Shields JA, Needle M, et al.: Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma. Ophthalmology 1997, 104:2101–2111.

    PubMed  CAS  Google Scholar 

  25. Shields CL, Santos MC, Diniz W, et al.: Thermotherapy for retinoblastoma. Arch Ophthalmol 1999, 117:885–893.

    PubMed  CAS  Google Scholar 

  26. Schueler AO, Jurklies C, Heimann H, et al.: Thermochemotherapy in hereditary retinoblastoma. Br J Ophthalmol 2003, 87:90–95.

    Article  PubMed  CAS  Google Scholar 

  27. Shields CL, Honavar SG, Meadows AT, et al.: Chemoreduction for unilateral retinoblastoma. Arch Ophthalmol 2002, 120:1653–1658.

    PubMed  Google Scholar 

  28. Kollmannsberger C, Hartmann JT, Kanz L, et al.: Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol 1998, 124:207–214.

    Article  PubMed  CAS  Google Scholar 

  29. Pedersen-Bjergaard J, Daugaard G: Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin and bleomycin for germ-cell tumours. Lancet 1991, 338:359–363.

    Article  PubMed  CAS  Google Scholar 

  30. Winick NJ, McKenna RW, Shuster JJ, et al.: Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 1993, 11:209–217.

    PubMed  CAS  Google Scholar 

  31. Felix CA: Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol 2001, 36:525–535.

    Article  PubMed  CAS  Google Scholar 

  32. Smith RE: Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and national surgical adjuvant breast and bowel project experience. Clin Breast Cancer 2003, 4:273–279.

    Article  PubMed  CAS  Google Scholar 

  33. Smith MA, Rubinstein L, Ungerleider RS: Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Pediatr Oncol 1994, 23:86–98.

    Article  PubMed  CAS  Google Scholar 

  34. Smith SM: Therapy-related leukemia associated with alkylating agents. Med Pediatr Oncol 2001, 36:536–540.

    Article  Google Scholar 

  35. Poi CH, Iberia RC, Hancock ML, et al.: Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991, 325:1682–1687.

    Article  Google Scholar 

  36. Smith MA, McCaffrey RP, Karp JE: The secondary leukemias: challenges and research directions. J Natl Cancer Inst 1996, 88:407–418

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Ophthalmology, Department of Head and Neck Surgery, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 441, Houston, TX, 77030, USA

    Dan S. Gombos

Authors
  1. Dan S. Gombos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patricia Chevez-Barrios
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dan S. Gombos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gombos, D.S., Chevez-Barrios, P. Current treatment and management of retinoblastoma. Curr Oncol Rep 9, 453–458 (2007). https://doi.org/10.1007/s11912-007-0063-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-007-0063-7

Keywords

Search

Navigation